[Combined use of goserelin acetate and human menopausal gonadotropin in the induction of follicular growth in a program of fertilization in vitro and embryo transfer]

What Was Tested

Researchers studied HMG (Human Menopausal Gonadotropin) and Goserelin in this clinical trial publication.

Serum levels of Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), 17-beta-estradiol (E2), Progesterone (P), were evaluated and transvaginal ultrasonographic examinations were performed during the treatment to assess the ovarian volume, the mean number and diameter of growing follicles and the endometrial morphology and thickness.

Who Took Part

The abstract describes 30 women taking part.

PubMed indexes the participants as adults, women only.

30 infertile women aged 32 to 37 years received a combined treatment with a long-acting slow-releasing Gn-RH-a and hMG to perform ovarian stimulation in a program of in-vitro fertilization.

How the Study Was Run

Oocyte retrieval was performed by transvaginal-ultrasound-guided approach, 24-36 hours after the administration of human chorionic gonadotropin (hCG).

What Was Measured

PubMed files the paper under topics including Embryo Transfer, Fertilization in Vitro, Gonadotropins, Goserelin, Ovarian Follicle and Ovulation Induction.

What This Means in Plain Language

This is a clinical trial of HMG (Human Menopausal Gonadotropin) and Goserelin in 30 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1994 (Minerva ginecologica), a journal based in Italy.

More context: the HMG (Human Menopausal Gonadotropin) compound page and the Goserelin compound page, all human trials.